Individualizing Immunotherapy in Non–Small Cell Lung Cancer

June 15, 2020

Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.

In season 1, episode 1 of Targeted Talks, community physician Jason R. Williams, MD, DABR, interventional radiologist, Williams Cancer Institute, leads a discussion with George R. Simon, MD, FACP, FCCP, medical oncologist, The University of Texas MD Anderson Cancer Center, about the use of immunotherapy in patients with non–small cell lung cancer (NSCLC), whether treated in an academic or community setting, and how this could be challenged with the discovery of a genetic driver alteration.

During the discussion, the 2 experts cover the pros and cons of immunotherapy use and how they differ in the community setting versus the academic setting, the available tools for profiling patients, promising immune checkpoint inhibitors for the treatment of NSCLC, key genetic drivers in NSCLC, and choosing the optimal subsequent therapy for patients with NSCLC.